JP7557374B2 - 免疫増強剤としてのウロリチンａ - Google Patents

免疫増強剤としてのウロリチンａ Download PDF

Info

Publication number
JP7557374B2
JP7557374B2 JP2020561032A JP2020561032A JP7557374B2 JP 7557374 B2 JP7557374 B2 JP 7557374B2 JP 2020561032 A JP2020561032 A JP 2020561032A JP 2020561032 A JP2020561032 A JP 2020561032A JP 7557374 B2 JP7557374 B2 JP 7557374B2
Authority
JP
Japan
Prior art keywords
compound
composition
formula
immune
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020561032A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522296A5 (cg-RX-API-DMAC10.html
JP2021522296A (ja
Inventor
リンシュ，クリストファー
シング，アヌラーグ
ダミーコ，ダヴィデ
アンドリュー，ペネロペ
ブランコ－ボーズ，ウィリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amazentis SA
Original Assignee
Amazentis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1807051.6A external-priority patent/GB201807051D0/en
Priority claimed from GBGB1807819.6A external-priority patent/GB201807819D0/en
Application filed by Amazentis SA filed Critical Amazentis SA
Publication of JP2021522296A publication Critical patent/JP2021522296A/ja
Publication of JP2021522296A5 publication Critical patent/JP2021522296A5/ja
Priority to JP2024159173A priority Critical patent/JP2024170634A/ja
Application granted granted Critical
Publication of JP7557374B2 publication Critical patent/JP7557374B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020561032A 2018-04-30 2019-04-30 免疫増強剤としてのウロリチンａ Active JP7557374B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024159173A JP2024170634A (ja) 2018-04-30 2024-09-13 免疫増強剤としてのウロリチンａ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1807051.6 2018-04-30
GBGB1807051.6A GB201807051D0 (en) 2018-04-30 2018-04-30 Biological enhancer
GB1807819.6 2018-05-14
GBGB1807819.6A GB201807819D0 (en) 2018-05-14 2018-05-14 Biological enhancer
PCT/EP2019/061093 WO2019211294A1 (en) 2018-04-30 2019-04-30 Urolithin a as immune enhancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024159173A Division JP2024170634A (ja) 2018-04-30 2024-09-13 免疫増強剤としてのウロリチンａ

Publications (3)

Publication Number Publication Date
JP2021522296A JP2021522296A (ja) 2021-08-30
JP2021522296A5 JP2021522296A5 (cg-RX-API-DMAC10.html) 2022-05-13
JP7557374B2 true JP7557374B2 (ja) 2024-09-27

Family

ID=66379918

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020561032A Active JP7557374B2 (ja) 2018-04-30 2019-04-30 免疫増強剤としてのウロリチンａ
JP2024159173A Pending JP2024170634A (ja) 2018-04-30 2024-09-13 免疫増強剤としてのウロリチンａ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024159173A Pending JP2024170634A (ja) 2018-04-30 2024-09-13 免疫増強剤としてのウロリチンａ

Country Status (7)

Country Link
US (3) US10792276B2 (cg-RX-API-DMAC10.html)
EP (1) EP3787615A1 (cg-RX-API-DMAC10.html)
JP (2) JP7557374B2 (cg-RX-API-DMAC10.html)
CN (1) CN112512517A (cg-RX-API-DMAC10.html)
BR (1) BR112020022159A2 (cg-RX-API-DMAC10.html)
MX (2) MX2020011619A (cg-RX-API-DMAC10.html)
WO (1) WO2019211294A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2866804T (pt) 2012-06-27 2023-12-18 Amazentis Sa Melhoria da autofagia ou aumento da longevidade por administração de urolitinas ou seus precursores
MX2020011619A (es) 2018-04-30 2021-01-15 Amazentis Sa Urolitina como mejorador inmunitario.
US20220241240A1 (en) * 2019-01-18 2022-08-04 Societe Des Produits Nestle S.A. Agents and methods for increasing stem cell function
GB201912107D0 (en) * 2019-08-22 2019-10-09 Amazentis Sa Combination
JP7897572B2 (ja) * 2020-11-26 2026-07-30 株式会社ダイセル サーチュイン６活性化剤
US11820751B2 (en) 2021-01-27 2023-11-21 Vandria Sa Urolithin derivatives and methods of use thereof
AU2022270331A1 (en) * 2021-05-05 2023-10-12 Ludwig Institute For Cancer Research Urolithin for increasing stem cell function
CN113813255B (zh) * 2021-10-20 2023-09-01 山东大学 尿石素a及其衍生物在肿瘤免疫治疗的应用
GB202219317D0 (en) * 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation
CN117180267B (zh) * 2023-10-25 2026-03-13 深圳市第三人民医院(深圳市肝病研究所) 一种尿石素a在制备药物中的应用及药物
WO2025224366A1 (en) * 2024-04-26 2025-10-30 Amazentis Sa Immune health improvers
GB202417829D0 (en) * 2024-12-04 2025-01-15 Amazentis Sa Formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015523362A (ja) 2012-06-27 2015-08-13 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2646177T3 (es) 2006-04-26 2017-12-12 The Regents Of The University Of California Usos terapéuticos de las urolitinas
CA2972013C (en) 2013-12-23 2020-04-28 Amazentis Sa Process-scale synthesis of urolithins
US20170367390A1 (en) * 2014-12-19 2017-12-28 Halo Life Science, Llc Use of ellagic acid dihydrate in food products and nutraceuticals
US20170304263A1 (en) * 2016-04-20 2017-10-26 John Michael Pezzuto Antioxidative stress compositions, methods of preparing and uses thereof
WO2019163176A1 (ja) * 2018-02-21 2019-08-29 株式会社ダイセル ウロリチン類を含有する破骨細胞分化抑制剤
MX2020011619A (es) 2018-04-30 2021-01-15 Amazentis Sa Urolitina como mejorador inmunitario.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015523362A (ja) 2012-06-27 2015-08-13 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Biochim Biophys Acta.，2018年，1862(1)，pp.61-70
Cell，2008年，132，pp.27-42
Immunity，2015年，43，pp.331-342
IUBMB Life，2018年，70(3)，pp.207-214
Nat Med.，2014年，20(5)，pp.503-510
PNAS，2005年，102(22)，pp.7922-7927
Trends Mol Med.，2016年，22(8)，pp.671-686

Also Published As

Publication number Publication date
MX2023013675A (es) 2024-01-08
US20230097072A1 (en) 2023-03-30
JP2024170634A (ja) 2024-12-10
US12109190B2 (en) 2024-10-08
US20190328703A1 (en) 2019-10-31
US10792276B2 (en) 2020-10-06
US20210085642A1 (en) 2021-03-25
MX2020011619A (es) 2021-01-15
BR112020022159A2 (pt) 2021-01-26
US11426380B2 (en) 2022-08-30
WO2019211294A1 (en) 2019-11-07
JP2021522296A (ja) 2021-08-30
CN112512517A (zh) 2021-03-16
EP3787615A1 (en) 2021-03-10
MX429002B (es) 2025-11-13

Similar Documents

Publication Publication Date Title
JP2024170634A (ja) 免疫増強剤としてのウロリチンａ
JPH11501284A (ja) アポトーシスを阻害する組成物、その組成物の精製方法およびその使用
EP1750707B1 (fr) Composition immunostimulante comprenant au moins un agoniste du récepteur Toll-like 7 ou du récepteur Toll-like 8 et un agoniste du récepteur Toll-like 4
JP7835407B2 (ja) 抗アレルギー用化粧品及び経皮外用剤
JP2021176855A (ja) プロテインｌ−イソアスパラギン酸メチルトランスフェラーゼ活性化用組成物
EP3578186A1 (en) Pharmaceutical composition for preventing or treating autoimmune disease, and method for producing same
JP2022058449A (ja) 自己免疫疾患の予防及び／又は治療のためのアジュバントの使用
US20250127844A1 (en) Peptide having hair loss prevention or hair growth promotion activity and use thereof
JP2021028296A (ja) ハプロ移植増強剤
KR102507470B1 (ko) 스트렙토코커스 피오게네스의 사균체 또는 SpeA 단백질을 포함하는 알레르기 질환의 예방 또는 치료용 약학적 조성물
JP2022517983A (ja) クローナル幹細胞を含むアトピー皮膚炎の予防または治療用薬学的組成物
CA3052131C (en) Pharmaceutical composition for preventing or treating hypersensitivity immune disease, and method for producing same
WO2024057892A1 (ja) 抗腫瘍免疫応答増強剤
KR102003958B1 (ko) 과민성 면역 질환의 예방 또는 치료용 약학적 조성물 및 그 제조방법
HK40007908A (en) Pharmaceutical composition for preventing or treating hypersensitivity immune disease, and method for producing same
Genito Generation of Immune Tolerance with Combined Pharmacological Agents
KR20240049114A (ko) 루미노코커스 그나부스를 유효성분으로 포함하는 염증성 피부질환 예방 또는 치료용 약학 조성물
Bryan et al. Immune Response and Infections in the Elderly
HK40007907A (en) Pharmaceutical composition for preventing or treating autoimmune disease, and method for producing same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240627

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240814

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240913

R150 Certificate of patent or registration of utility model

Ref document number: 7557374

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150